Navigation Links
Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
Date:4/23/2009

s or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidate. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG and GlaxoSmithKline, respectively; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... The Academy of Model Aeronautics has ... graduates from across the nation. , The Academy of ... AMA Youth Members with scholarships to pursue technical careers. ... has awarded nearly $900,000 to college-bound aero-modelers. The scholarships ... and individuals, AMA member donations, a portion of AMA ...
(Date:5/29/2015)... -- Asthma treatment could   see ... treatments enter arena, says   GBI Research ... several of the leading asthma brands, such as Advair ... the global market for asthma treatment is set to ...   New analysis from business intelligence provider ...
(Date:5/29/2015)... 2015 Market Publishers Ltd and ... a partnership agreement for quality market research promotion ... and sell research reports worked out by Chem-Report. ... commented upon the agreement: “Chem-Report is a Chinese ... and chemical markets on global and country levels. ...
(Date:5/29/2015)... NEW YORK , May 29, 2015 /PRNewswire/ ... a specialty pharmaceutical and medical device company focused ... of primary and metastatic liver cancers, announces that ... the treatment of uveal melanoma patients with hepatic ... Delivery System, were highlighted in an on-line abstract ...
Breaking Biology Technology:Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5
... 2011 Engineers and scientists collaborating at Harvard University ... world,s first programmable nanoprocessor. The groundbreaking prototype computer ... journal Nature , represents a significant step forward ... assembled from synthesized nanometer-scale components. It also represents ...
... 9, 2011 Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) ... special meeting of shareholders, to be held on February ... Research Triangle Park Marriott, 4700 Guardian Drive, Durham, North Carolina 27703. ... announced merger agreement under which Grifols (GRF.MC) will acquire ...
... LOUIS, Feb. 9, 2011 HIGHLIGHTS:2010 Results (all ... Q4 2010 reported sales were $582 million, a new quarterly high. ... currency adjusted basis, respectively.  Full year 2010 sales increased 6% and ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring ...
Cached Biology Technology:Researchers at Harvard and MITRE produce world's first programmable nanoprocessor 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13
(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... $7 million grant from the National Institutes of ... Hospital translate new scientific findings and technological developments ... grant designates Nationwide Children,s Hospital as a Paul ... of three national award recipients in 2010. ...
... comparing two species of ants, Shelley Berger, PhD, the ... Pennsylvania, and colleagues Danny Reinberg, PhD, New York University, ... an important new avenue of research for epigenetics -- ... particular genes affects an organism,s characteristics, development, and even ...
... message: Find out what,s new (and important) ... international reporters, Book hotel rooms now for the best selection, ... 1. Find out what,s new (and important) in the ... Fall Meeting returns to the Moscone Convention Center, located at ...
Cached Biology News:$7 million grant designates Nationwide Children's as Wellstone Center 2Genome comparison of ants establishes new model species for molecular research 2Genome comparison of ants establishes new model species for molecular research 3Genome comparison of ants establishes new model species for molecular research 4AGU 2010 Fall Meeting: News media registration opens, book hotels now 2AGU 2010 Fall Meeting: News media registration opens, book hotels now 3AGU 2010 Fall Meeting: News media registration opens, book hotels now 4
ANTI CORTIS BIN GLOB...
EoProbe Eosinophil Staining Kit, 1 Kit...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Request Info...
Biology Products: